Femtobiomed (XKRX:327610) Interest Expense : ₩0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Femtobiomed Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Femtobiomed's interest expense for the six months ended in Dec. 2024 was ₩ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Femtobiomed's Operating Income for the six months ended in Dec. 2024 was ₩ -5,322.0 Mil. Femtobiomed's Interest Expense for the six months ended in Dec. 2024 was ₩ 0.0 Mil. GuruFocus does not calculate Femtobiomed's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Femtobiomed Interest Expense Historical Data

The historical data trend for Femtobiomed's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femtobiomed Interest Expense Chart

Femtobiomed Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-9.93

-104.68

-0.25

-0.11

Femtobiomed Semi-Annual Data
	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Interest Expense	Get a 7-Day Free Trial			-9.93	-104.68	-0.25	-0.11	-

Femtobiomed Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩0.0 Mil.

Femtobiomed (XKRX:327610) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Femtobiomed's Interest Expense for the six months ended in Dec. 2024 was ₩0.0 Mil. Its Operating Income for the six months ended in Dec. 2024 was ₩-5,322.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2024 was ₩33.1 Mil.

Femtobiomed's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Femtobiomed's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Femtobiomed Inc has enough cash to cover all of its debt. Its financial situation is stable.

Femtobiomed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Femtobiomed Inc (XKRX:327610) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Pangyo-ro 228 (ibaegisippal) beo, Sampyeong-dong, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13487

Website

https://www.femtobiomed.com

Femtobiomed Inc is a South Korea based company engaged in developing a cargo-free intracellular delivery platform called Cell Shot Platform. It is focused on using this technology to work on cell-based therapeutic pipelines.

Femtobiomed Headlines

No Headlines